Age essential when testing drugs

Anders Rane has been arguing that genes and age are both important factors in understanding how medicines affect individuals. Only last year, the EU established regulations stating that pharmaceuticals must be tested for children as well as for adults.

Se upp för konsulten!

Kliniska prövningar blir allt dyrare i Sverige och många företag vänder sig utomlands för att gör sina studier. Men företagen måste vara klara över vad de behöver hjälp med och se igenom CRO-företagens säljarfloskler, annars riskerar outsouringaffären att bli allt annat än lyckad.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

Ny hövding till Symbion

Jørgen Bardenfleth, chef för danska Microsoft har valts in som ny styrelseordförande i den danska forskningsparken.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Re-painting the big pig-ture

Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.

Lundbeck divests companies

The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.

Less scars with new product

A new Swedish product for post surgical scar formation enters clinical development.

Medicult needs a word of advice

Medicult Board retains advisers, regarding the previous offer from Vitrolife.

Lytix calls in cash

Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.

Biotech goes white and bright

White biotech could become Denmark's next blossoming business area.

Eli Lilly writes biotech fine history

The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.

Think outside the... brain

Riitta Hari from the Brain Research Unit at the Helsinki University of Technology has recently stated that the mind is more than just the brain.

Harmony prevents dementia

People who are active, outgoing and relaxed may be less likely to develop dementia, according to a new study from Karolinska Institutet.

New nanotech professor to DTU

The Danish University of Technology, DTU, has appointed Kristoffer Almdal as professor to DTU Nanotech.

Polymer guru new dean at DTU

The Technical University of Denmark, DTU, has appointed a well-known profile from the Polymer Center as a new dean.

LEO Pharma - International Clinical Trial Manager

Medicult disclaims Swedish offer

The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.

New map of eye proteins

A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.

SDU professor helps EU

Mette Præst Knudsen from the University of Southern Denmark, SDU, has been appointed as an expert member in an EU politics group.

Swiss allergy therapy convinces

Cytos Biotechnology presents promising results in a study of a new therapy against allergy and asthma.